In the latest trading session, Kamada closed at $5.76, marking a +0.17% move from the previous day. The stock lagged the S&P 500's daily gain of 0.21%. At the same time, the Dow added 0.64%, and the tech-heavy Nasdaq lost 0.05%.
Coming into today, shares of the biopharmaceutical had lost 4.49% in the past month. In that same time, the Medical sector lost 0.07%, while the S&P 500 gained 2.57%.
Wall Street will be looking for positivity from KMDA as it approaches its next earnings report date. In that report, analysts expect KMDA to post earnings of $0.05 per share. This would mark year-over-year growth of 66.67%. Meanwhile, our latest consensus estimate is calling for revenue of $22.87 million, up 31.14% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.47 per share and revenue of $126.91 million, which would represent changes of -17.54% and +10.87%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for KMDA. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. KMDA is holding a Zacks Rank of #1 (Strong Buy) right now.
In terms of valuation, KMDA is currently trading at a Forward P/E ratio of 12.32. This valuation marks a discount compared to its industry's average Forward P/E of 21.19.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 79, putting it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
Kamada (KMDA) Gains But Lags Market: What You Should Know
In the latest trading session, Kamada closed at $5.76, marking a +0.17% move from the previous day. The stock lagged the S&P 500's daily gain of 0.21%. At the same time, the Dow added 0.64%, and the tech-heavy Nasdaq lost 0.05%.
Coming into today, shares of the biopharmaceutical had lost 4.49% in the past month. In that same time, the Medical sector lost 0.07%, while the S&P 500 gained 2.57%.
Wall Street will be looking for positivity from KMDA as it approaches its next earnings report date. In that report, analysts expect KMDA to post earnings of $0.05 per share. This would mark year-over-year growth of 66.67%. Meanwhile, our latest consensus estimate is calling for revenue of $22.87 million, up 31.14% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.47 per share and revenue of $126.91 million, which would represent changes of -17.54% and +10.87%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for KMDA. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. KMDA is holding a Zacks Rank of #1 (Strong Buy) right now.
In terms of valuation, KMDA is currently trading at a Forward P/E ratio of 12.32. This valuation marks a discount compared to its industry's average Forward P/E of 21.19.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 79, putting it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.